← Leaderboards
Igor Astsaturov
Fox Chase Cancer Center
$3,975,720
Attributed
$5,075,436
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $736.8K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,075,436 · 8
By mechanism
R01$2,513,369 · 2
R21$1,781,763 · 4
K22$592,304 · 1
R03$188,000 · 1
Top collaborators
- Edna Cukierman2 shared
- Efrat Dotan2 shared
- Anthony J. Olszanski2 shared
- David L Wiest2 shared
- Jonathan A Soboloff1 shared
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Margie L. Clapper$16,783,564
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSignal TransductionCellsTumorCancer CellProteinsPathway InteractionsResistanceBasePharmaceutical PreparationsNeoplastic CellLinkSterolsMetabolicMouse ModelCell MembraneGrowthCholesterolMalignant Neoplasm Of PancreasCetuximabBioinformaticsEnzymesIn VivoEpithelial Cells
Grant awards (19)
Targeting anoctamin 6 to disrupt trogocytosis of cancer-associated fibroblasts$642,755
R01 · FY2025 · CA · contact PI
Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer$94,000
R03 · FY2025 · CA · contact PI
A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma$208,738
R21 · FY2024 · CA · contact PI
Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer$94,000
R03 · FY2024 · CA · contact PI
A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma$263,670
R21 · FY2023 · CA · contact PI
Neoadjuvant Stroma Modification in Pancreatic Cancer$249,135
R21 · FY2022 · CA · contact PI
Neoadjuvant Stroma Modification in Pancreatic Cancer$210,508
R21 · FY2021 · CA · contact PI
Oncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cells$200,481
R21 · FY2020 · CA · contact PI
Oncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cells$236,146
R21 · FY2019 · CA · contact PI
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer$379,725
R01 · FY2018 · CA · contact PI
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer$379,725
R01 · FY2017 · CA · contact PI
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer$370,388
R01 · FY2016 · CA · contact PI
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer$370,388
R01 · FY2015 · CA · contact PI
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer$370,388
R01 · FY2014 · CA · contact PI
Regulation of EGFR by SC4MOL- and NSDHL-Dependent Trafficking$218,966
R21 · FY2013 · CA · contact PI
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy$195,961
K22 · FY2013 · CA · contact PI
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy$197,098
K22 · FY2012 · CA · contact PI
Regulation of EGFR by SC4MOL- and NSDHL-Dependent Trafficking$194,119
R21 · FY2012 · CA · contact PI
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy$199,245
K22 · FY2011 · CA · contact PI